stoxline Quote Chart Rank Option Currency Glossary
  
Adlai Nortye Ltd. American Depositary Shares (ANL)
12.4  2.34 (23.26%)    04-19 16:00
Open: 10.39
High: 12.4454
Volume: 15,905
  
Pre. Close: 10.06
Low: 10.39
Market Cap: 211(M)
Technical analysis
2024-04-19 5:07:44 PM
Short term     
Mid term     
Targets 6-month :  16.03 1-year :  20.41
Resists First :  13.72 Second :  17.47
Pivot price 10.54
Supports First :  7.65 Second :  6.36
MAs MA(5) :  11.01 MA(20) :  10.16
MA(100) :  9.2 MA(250) :  0
MACD MACD :  0.6 Signal :  0.5
%K %D K(14,3) :  36 D(3) :  32.1
RSI RSI(14): 65.3
52-week High :  17.47 Low :  7.11
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ANL ] has closed below upper band by 5.3%. Bollinger Bands are 94.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 12.46 - 12.51 12.51 - 12.56
Low: 10.28 - 10.33 10.33 - 10.38
Close: 12.31 - 12.4 12.4 - 12.48
Company Description

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.

Headline News

Fri, 09 Feb 2024
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In ... - Markets Insider

Tue, 03 Oct 2023
Adlai Nortye Ltd. Announces Closing of Initial Public Offering - GlobeNewswire

Fri, 29 Sep 2023
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering - GlobeNewswire

Sun, 21 Apr 2024

Sun, 21 Apr 2024

Sun, 21 Apr 2024

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 37 (M)
Shares Float 19 (M)
Held by Insiders 6.9 (%)
Held by Institutions 0.2 (%)
Shares Short 6 (K)
Shares Short P.Month 3 (K)
Stock Financials
EPS -3.32
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -24.38
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.89
Qtrly Earnings Growth 0 %
Operating Cash Flow -38 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -3.74
PEG Ratio 0
Price to Book value -0.51
Price to Sales 0
Price to Cash Flow -11.96
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android